Ali Mirza1, Jessica D Forbes2, Feng Zhu1, Charles N Bernstein3, Gary Van Domselaar4, Morag Graham4, Emmanuelle Waubant5, Helen Tremlett6. 1. Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada. 2. Department of Internal Medicine, University of Manitoba, University of Manitoba IBD Clinical and Research Centre, Winnipeg, MB, Canada; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada; Department of Laboratory Medicine & Pathobiology, University of Toronto, ON, Canada. 3. Department of Internal Medicine, University of Manitoba, University of Manitoba IBD Clinical and Research Centre, Winnipeg, MB, Canada. 4. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada. 5. University of California San Francisco, San Francisco, CA, United States. 6. Djavad Mowafaghian Centre for Brain Health, Faculty of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada. Electronic address: helen.tremlett@ubc.ca.
Abstract
BACKGROUND: To systematically review and synthesize the literature on the multiple sclerosis (MS) gut microbiota composition as compared to persons without MS. METHODS: We systematically searched MEDLINE, EMBASE, and Web of Science databases for relevant published articles (2008-2018). RESULTS: Of 415 articles identified ten fulfilled criteria. All studies used a case-control design, six sourced participants from the US, two Germany, one Italy, and one Japan. Nine focused exclusively on adults and one on children, totaling 286 MS and 296 control participants. Over 90% of cases had relapsing-remitting MS; disease duration ranged from 10.6 ± 6.5 months to 15.3 ± 8.6 years (mean±SD). Nine studies examined stool and one evaluated duodenal mucosa. Diverse platforms were used to quantify microbes: Illumina MiSeq, Roche 454, microarray, and fluorescence in situ hybridization. None of eight studies reported a significant alpha-diversity differences between cases and controls. Two of seven studies reported a difference in beta-diversity (P ≤ 0.002). At the taxa-level, ≥2 studies observed: lower relative abundance of Prevotella, Faecalibacterium prausnitzii, Bacteroides coprophilus, Bacteroides fragilis, and higher Methanobrevibacter and Akkermansia muciniphila in MS cases versus controls. Exposure to an immunomodulatory drug (IMD), relative to no exposure, was associated with individual taxonomic differences in three of three studies. CONCLUSION: Gut microbiota diversity did not differ between MS cases and controls in the majority of studies. However, taxonomic differences were found, with consistent patterns emerging across studies. Longitudinal studies are warranted to elucidate the relationship between IMD exposure and differences in the gut microbiota composition.
BACKGROUND: To systematically review and synthesize the literature on the multiple sclerosis (MS) gut microbiota composition as compared to persons without MS. METHODS: We systematically searched MEDLINE, EMBASE, and Web of Science databases for relevant published articles (2008-2018). RESULTS: Of 415 articles identified ten fulfilled criteria. All studies used a case-control design, six sourced participants from the US, two Germany, one Italy, and one Japan. Nine focused exclusively on adults and one on children, totaling 286 MS and 296 control participants. Over 90% of cases had relapsing-remitting MS; disease duration ranged from 10.6 ± 6.5 months to 15.3 ± 8.6 years (mean±SD). Nine studies examined stool and one evaluated duodenal mucosa. Diverse platforms were used to quantify microbes: Illumina MiSeq, Roche 454, microarray, and fluorescence in situ hybridization. None of eight studies reported a significant alpha-diversity differences between cases and controls. Two of seven studies reported a difference in beta-diversity (P ≤ 0.002). At the taxa-level, ≥2 studies observed: lower relative abundance of Prevotella, Faecalibacterium prausnitzii, Bacteroides coprophilus, Bacteroides fragilis, and higher Methanobrevibacter and Akkermansia muciniphila in MS cases versus controls. Exposure to an immunomodulatory drug (IMD), relative to no exposure, was associated with individual taxonomic differences in three of three studies. CONCLUSION: Gut microbiota diversity did not differ between MS cases and controls in the majority of studies. However, taxonomic differences were found, with consistent patterns emerging across studies. Longitudinal studies are warranted to elucidate the relationship between IMD exposure and differences in the gut microbiota composition.
Authors: Ali I Mirza; Feng Zhu; Natalie Knox; Jessica D Forbes; Gary Van Domselaar; Charles N Bernstein; Morag Graham; Ruth Ann Marrie; Janace Hart; E Ann Yeh; Douglas L Arnold; Amit Bar-Or; Julia O'Mahony; Yinshan Zhao; William Hsiao; Brenda Banwell; Emmanuelle Waubant; Helen Tremlett Journal: Neurology Date: 2021-12-22 Impact factor: 9.910
Authors: Laura M Cox; Amir Hadi Maghzi; Shirong Liu; Stephanie K Tankou; Fyonn H Dhang; Valerie Willocq; Anya Song; Caroline Wasén; Shahamat Tauhid; Renxin Chu; Mark C Anderson; Philip L De Jager; Mariann Polgar-Turcsanyi; Brian C Healy; Bonnie I Glanz; Rohit Bakshi; Tanuja Chitnis; Howard L Weiner Journal: Ann Neurol Date: 2021-04-30 Impact factor: 11.274
Authors: Stanley L Cohan; Barry A Hendin; Anthony T Reder; Kyle Smoot; Robin Avila; Jason P Mendoza; Bianca Weinstock-Guttman Journal: CNS Drugs Date: 2021-07-06 Impact factor: 5.749